Table 2.
Comparison of clinicopathological characteristics between investigation cohort (n = 35) and validation cohort (n = 22)
| Categorical variables (n (%)) | Continuous variables (mean ± SE) | ||||||
|---|---|---|---|---|---|---|---|
| Investigation | Validation | P value | Investigation | Validation | P value | ||
| Male gender | 27 (77.1) | 19 (86.4) | 0.502 | Age (year) | 62.7 ± 1.9 | 60.2 ± 2.4 | 0.429 |
| HBV infection | 23 (65.7) | 11 (50.0) | 0.277 | BMI (Kg/m2) | 23.9 ± 0.5 | 25.6 ± 0.7 | 0.063 |
| HCV infection | 8 (22.9) | 9 (40.9) | 0.234 | ICG-15 (%) | 9.53 ± 0.88 | 11.44 ± 1.64 | 0.316 |
| AFP > 15 ng/mL | 21 (60.0) | 10 (45.5) | 0.413 | AFP (ng/mL) | 16096 ± 12568 | 17938 ± 17777 | 0.931 |
| Major procedure | 9 (25.7) | 6 (27.3) | 1.000 | CEA (ng/mL) | 6.07 ± 4.07 | 1.57 ± 0.20 | 0.361 |
| Encapsulation | 28 (80.0) | 22 (100.0) | 0.036 | CA 19-9 (U/mL) | 26.6 ± 3.7 | 22.1 ± 3.9 | 0.421 |
| Vascular invasion | 14 (40.0) | 10 (45.5) | 0.785 | Size (cm) | 4.59 ± 0.61 | 4.05 ± 0.68 | 0.557 |
| Daughter nodules | 4 (11.4) | 2 (9.1) | 1.000 | ||||
| Tumor rupture | 3 (8.6) | 1 (4.5) | 1.000 | ||||
| Cirrhosis | 14 (40.0) | 13 (59.1) | 0.184 | ||||
| Edmondson and Steiner Grade (I/II/III/IV) | 4(11.8)/10(28.6)/18(52.9)/3(8.8) | 3(13.6)/13(59.1)/5(22.7)/1(4.5) | 0.073 | ||||